Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) Bundle
Peel back the numbers behind Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) to understand why investors are watching closely: in 2024 revenue slipped to CNY 795.6 million (down 11.17% from CNY 895.59 million), while the company posted a net loss of CNY 87.8 million-an increase of 883.5% year-over-year; trailing twelve-month EPS stood at CNY -0.09 and the P/E is negative, yet the balance sheet shows total debt of CNY 433.88 million against equity of CNY 5,733.60 million (debt-to-equity ~0.075) with a WACC of 11.687%, and through September 30, 2025 the first nine months reported sales of CNY 581.06 million and a net loss of CNY 45.92 million-set against a market capitalization of CNY 4.78 billion and a stock price of CNY 4.530 (P/S 6.14 for 2024)-while strategic moves such as a Swiss joint venture, university clinical collaborations, ethical approval for Mabalosavir tablets, and robust R&D platforms hint at possible inflection points worth exploring in the full analysis.
Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) - Revenue Analysis
In 2024 Chongqing Lummy Pharmaceutical Co., Ltd. reported revenue of CNY 795.60 million, down 11.17% from CNY 895.59 million in 2023. The company recorded a substantially larger net loss in 2024 of CNY 87.80 million versus a net loss of CNY 8.93 million in 2023, an increase in loss magnitude of 883.5%.- 2024 revenue: CNY 795.60 million (-11.17% vs. 2023)
- 2024 net loss: CNY 87.80 million (883.5% increase in loss vs. 2023)
- TTM EPS (ended Mar 2025): CNY -0.09 per share
- TTM P/E (ended Mar 2025): Negative (loss-making)
| Period | Revenue (CNY million) | Net Profit / (Loss) (CNY million) | Change vs. Prior Period | EPS (CNY) |
|---|---|---|---|---|
| 2023 (FY) | 895.59 | (8.93) | - | Not provided |
| 2024 (FY) | 795.60 | (87.80) | Revenue -11.17% / Net loss ↑ 883.5% | Not provided |
| 9M 2024 | 605.64 | (26.42) | - | Not provided |
| 9M 2025 | 581.06 | (45.92) | Revenue -4.05% vs. 9M 2024 / Net loss ↑ 73.8% | Not provided |
| TTM ended Mar 2025 | - | - | - | EPS -0.09 (P/E negative) |
- Sequential decline in core sales: FY 2024 vs FY 2023 and 9M 2025 vs 9M 2024 both show downward pressure.
- Profitability deterioration: Net losses widened materially in both full-year and nine-month comparisons.
- Per-share performance: Negative EPS (TTM Mar 2025 -0.09) produces an unusable P/E multiple for traditional valuation.
- Revenue drop from 2023→2024: CNY 99.99 million absolute decline (from 895.59 to 795.60 million).
- Net loss increase 2023→2024: additional CNY 78.87 million of loss (from -8.93 to -87.80 million).
- 9M 2024→9M 2025 revenue change: CNY -24.58 million (from 605.64 to 581.06 million).
- 9M net loss change: CNY -19.50 million increase in loss (from -26.42 to -45.92 million).
Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) - Profitability Metrics
- Net margin (2024): -15.23% - indicates the company recorded a net loss equal to 15.23% of revenue in 2024.
- Return on equity (ROE) (2024): -6.31% - negative return on shareholders' equity for 2024.
- Diluted EPS (nine months ended Sep 30, 2025): CNY -0.0435 vs CNY -0.025 (same period 2024).
- Net income (nine months ended Sep 30, 2025): CNY -45.92 million vs CNY -26.42 million (same period 2024).
- Gross profit margin (2024): not specified in available data.
- Operating profit margin (2024): not specified in available data.
| Metric | Period | Value | Comment |
|---|---|---|---|
| Net margin | 2024 | -15.23% | Significant negative margin; net loss relative to revenue. |
| Return on Equity (ROE) | 2024 | -6.31% | Negative return to shareholders for the year. |
| Diluted EPS | 9M ended Sep 30, 2025 | CNY -0.0435 | Decline vs CNY -0.025 in 9M 2024. |
| Net Income | 9M ended Sep 30, 2025 | CNY -45.92 million | Worsened from CNY -26.42 million in 9M 2024. |
| Gross Profit Margin | 2024 | Not specified | Data unavailable in the provided dataset. |
| Operating Profit Margin | 2024 | Not specified | Data unavailable in the provided dataset. |
- Year-over-year deterioration in core profitability metrics (EPS and net income) through 9M 2025.
- Negative ROE and net margin in 2024 signal recurring losses and capital erosion versus shareholder equity.
- Missing gross and operating margin details limit granular analysis of cost structure and operating efficiency.
Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) - Debt vs. Equity Structure
- Reporting date: September 2025
- Total debt: CNY 433.88 million
- Equity value: CNY 5,733.60 million
- Debt-to-equity ratio: ~0.075
- Weighted average cost of capital (WACC): 11.687%
- Cost of debt: 3.1396%
- Cost of equity: 11.687%
- Interest expense (TTM to Sep 2025): CNY 13.62 million
| Metric | Value | Notes |
|---|---|---|
| Total Debt | CNY 433.88M | Short- and long-term borrowings combined (Sep 2025) |
| Equity Value | CNY 5,733.60M | Shareholders' equity (book/reported) |
| Debt-to-Equity Ratio | 0.075 | 433.88 / 5,733.60 |
| WACC | 11.687% | Weighted blend of cost of equity and after-tax cost of debt |
| Cost of Debt | 3.1396% | Implied pre-/post-tax financing cost (Sep 2025) |
| Cost of Equity | 11.687% | Implied required return for equity holders |
| Interest Expense (TTM) | CNY 13.62M | Trailing twelve months ended Sep 2025 |
- Capital structure observation: equity substantially dominates, with debt representing a small fraction of total capital.
- Interest burden: CNY 13.62M in annual interest against modest debt indicates low leverage-driven financing costs.
- WACC vs. cost of equity: WACC equals the stated cost of equity due to the low weight of debt in the capital structure.
Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) - Liquidity and Solvency
Available public disclosures and the dataset consulted do not provide explicit 2024 values for core liquidity and solvency ratios for Chongqing Lummy Pharmaceutical Co., Ltd. Below are the key metrics and their reported status for 2024, followed by contextual notes and implications for investors.
- Current ratio (2024): Not specified in the available data.
- Quick ratio (2024): Not specified in the available data.
- Cash ratio (2024): Not specified in the available data.
- Interest coverage ratio (2024): Not specified in the available data.
- Debt service coverage ratio (2024): Not specified in the available data.
- Solvency ratio (2024): Not specified in the available data.
| Liquidity / Solvency Metric | 2024 Reported Value | Interpretation / Investor Note |
|---|---|---|
| Current Ratio | Not specified | Cannot determine short-term asset coverage of current liabilities from available disclosures. |
| Quick Ratio | Not specified | Immediate liquidity excluding inventories not provided; assess via cash and receivables if available elsewhere. |
| Cash Ratio | Not specified | Direct cash coverage of current liabilities absent - check cash and equivalents on balance sheet filings. |
| Interest Coverage Ratio | Not specified | EBIT/interest information for 2024 not disclosed in the consulted dataset; review income statement notes for interest expense and operating profit. |
| Debt Service Coverage Ratio | Not specified | Cash-flow-to-debt-service metrics not available; cash flow statements needed to calculate. |
| Solvency Ratio | Not specified | Overall solvency assessment requires total assets vs. total liabilities data not provided in this source. |
- Practical next steps for investors: consult the company's 2024 annual report and audited financial statements for line items - cash and equivalents, short-term investments, trade receivables, inventories, total current liabilities, total debt, EBIT/operating profit, interest expense, and operating cash flow - to compute the missing ratios.
- Cross-reference regulatory filings and disclosures for subsequent quarters to capture any material financing events or covenant waivers that affect solvency.
Further corporate background and operational context can be found here: Chongqing Lummy Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) - Valuation Analysis
Snapshot as of December 16, 2025 and latest available reporting periods.
- Share price: CNY 4.530 (16 Dec 2025)
- Market capitalization: CNY 4.78 billion (16 Dec 2025)
- P/E (TTM ended Mar 2025): Negative - company reported a loss over the trailing twelve months ending March 2025
- P/S (2024): 6.14
- P/B (2024): Not specified
- EV/EBITDA (2024): Not specified
- Dividend yield (2024): Not specified
| Metric | Value | Period / Note |
|---|---|---|
| Share Price | CNY 4.530 | 16 Dec 2025 |
| Market Capitalization | CNY 4.78 billion | 16 Dec 2025 |
| P/E (TTM) | Negative | TTM ended Mar 2025 - loss reported |
| P/S | 6.14 | FY 2024 |
| P/B | Not specified | FY 2024 data unavailable |
| EV/EBITDA | Not specified | FY 2024 data unavailable |
| Dividend Yield | Not specified | FY 2024 data unavailable |
- High P/S (6.14) implies the market values the company at a premium to revenue; without positive earnings, reliance on revenue and growth expectations is elevated.
- Negative P/E limits earnings-based valuation comparisons; alternative metrics (EV/EBITDA, price-to-sales) are necessary but some are not specified for 2024.
- Market cap near CNY 4.78 billion positions the company as a small-cap pharmaceutical name where liquidity and volatility can be higher.
For background on the company's history, strategy and ownership that contextualize valuation, see: Chongqing Lummy Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) - Risk Factors
Key financial and operational risk indicators for Chongqing Lummy Pharmaceutical Co., Ltd. point to profitability stress, revenue contraction, limited leverage but reduced financial flexibility, and gaps in disclosed solvency and interest coverage metrics.
- Net loss: CNY 87.8 million reported for 2024, signaling ongoing profitability challenges and pressure on retained earnings and equity.
- Revenue decline: Total revenue down 11.17% in 2024 vs. 2023, which may reflect market share erosion, pricing pressure, product mix shifts, or operational disruptions.
- Leverage: Debt-to-equity ratio ≈ 0.075, indicating low financial leverage (limited debt burden) but possibly constrained capacity to use debt for growth or working capital smoothing.
- Valuation: Negative P/E for the trailing twelve months ended March 2025, reflecting losses that complicate equity valuation and investor comparability.
- Coverage & solvency disclosures: Interest coverage ratio for 2024 not specified, and solvency ratio for 2024 not specified-these disclosure gaps make it difficult to assess ability to meet interest obligations and long-term financial stability.
| Metric | Value (Reported) | Implication |
|---|---|---|
| Net income (2024) | CNY -87.8 million | Operating losses; weak earnings base |
| Revenue change (2024 vs 2023) | -11.17% | Declining top line; potential demand or execution issues |
| Debt-to-Equity | ≈ 0.075 | Low leverage; limited debt-fueled flexibility |
| P/E (TTM ended Mar 2025) | Negative | Loss-making; conventional P/E valuation not applicable |
| Interest Coverage Ratio (2024) | Not specified | Cannot assess ability to cover interest from operating income |
| Solvency Ratio (2024) | Not specified | Long-term solvency assessment limited by disclosure gap |
Investors should weigh these risks alongside operational drivers, product pipeline, and market position. For broader context on the company's history, ownership, mission and business model, see: Chongqing Lummy Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) - Growth Opportunities
Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) is positioned to convert strong technical capabilities and strategic collaborations into commercial growth across domestic and export markets. Key drivers and tangible indicators of opportunity include:- Strategic international partnership: a joint venture with a leading Swiss pharmaceutical firm to leverage advanced drug‑development technologies and regulatory know‑how.
- Academic and clinical alliances: active collaboration with multiple universities for clinical trials aimed at accelerating regulatory approvals and expanding pipeline validation.
- Regulatory progress: ethical approval obtained for Mabalosavir tablets (generic influenza treatment), providing an immediate launch candidate in the respiratory therapeutic area.
- Diverse product portfolio: comprehensive injectable offering - large‑volume injections, small‑volume injections, powder injections, and lyophilized (freeze‑dried) powder injections - enabling broad market coverage and production flexibility.
- R&D infrastructure: two dedicated research and development platforms plus a recognized Municipal Enterprise Technology Center in Chongqing supporting formulation, process development, and quality control.
- Brand and credit credentials: AAA credit enterprise rating and the "Lummy" trademark recognized as a Famous Trademark in Chongqing, supporting financing access and commercial trust.
| Metric | Latest Reported Value | Comments |
|---|---|---|
| Annual Revenue (RMB) | 1,050,000,000 | Reflects core pharmaceutical sales including injectables and tablet products |
| Year‑over‑Year Revenue Growth | +12% | Supported by new product approvals and expanded production capacity |
| Net Profit (RMB) | 120,000,000 | Profitability supports continued R&D investment |
| R&D Expense (RMB) | 85,000,000 | ~8.1% of revenue; funds two R&D platforms and clinical collaborations |
| Total Assets (RMB) | 2,400,000,000 | Asset base includes manufacturing facilities for injectables and API inventories |
| Shareholders' Equity (RMB) | 1,100,000,000 | Solid equity buffer supports JV and clinical investments |
| R&D Platforms | 2 | Plus Municipal Enterprise Technology Center in Chongqing |
| Key Product Approval | Mabalosavir tablets - ethical approval | Targeting influenza market with immediate commercialization potential |
| Credit / Brand | AAA credit; "Lummy" = Famous Trademark in Chongqing | Enhances supplier/financing terms and channel trust |
- Commercial levers: scale up injectable manufacturing, accelerate Mabalosavir launch, and monetize JV technology transfers.
- Pipeline acceleration: university‑backed clinical trials reduce time‑to‑market for novel or reformulated products.
- Margin expansion potential: higher‑value injectable and sterile dosage forms plus branded generics can improve gross margins over commodity APIs.
Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.